Industry expert Ulrik Mouritzen M.D. appointed Chief Executive Officer Funding to advance lead asset to phase 1b clinical trial and further build pipeline COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR […]